Top

The European Journal of Health Economics

Published in:

01-07-2009 | Original Paper

Hybrid risk adjustment for pharmaceutical benefits

Authors: Manuel García-Goñi, Pere Ibern, José María Inoriza

Published in: The European Journal of Health Economics | Issue 3/2009

Abstract

This paper analyses the application of hybrid risk adjustment versus either prospective or concurrent risk adjustment formulae in the context of funding pharmaceutical benefits for the population of an integrated healthcare delivery organisation in Catalonia during years 2002 and 2003. We apply a mixed formula and find that, compared to prospective only models, a hybrid risk adjustment model increases incentives for efficiency in the provision for low risk individuals in health organisations, not only as a whole but also within each internal department, by reducing within-group variation of drug expenditures.

Zuvekas, S.H., Cohen, J.W.: Prescription drugs and the changing concentration of health care expenditures. Health Aff. 26(1), 249–257 (2007). doi:10.1377/hlthaff.26.1.249 CrossRef

Berk, M.L., Monheit, A.C.: The concentration of health care expenditures, revisited. Health Aff 20(2), 9–18 (2001). doi:10.1377/hlthaff.20.2.9 CrossRef

Morgan, S.G.: Prescription drug expenditures and population demographics. Health Serv. Res 41(2), 411–428 (2006). doi:10.1111/j.1475-6773.2005.00495.x CrossRef

Ibern, P., Inoriza, J.M.: La despesa farmaceutica segons morbiditat. Cap.5 en Estudis d’Economia de la Salut, pp 111–138. Generalitat de Catalunya, Departement de Salut, Barcelona. http://www.gencat.net/salut/depsan/units/sanitat/pdf/estudissalut2007.pdf (2006)

Rice, N., Dixon, P., Lloyd, D.C., Roberts, D.: Derivation of a needs based capitation formula for allocating prescribing budgets to health authorities and primary care groups in England: regression analysis. BMJ 320, 284–288 (2000). doi:10.1136/bmj.320.7230.284 CrossRef

García-Sempere, A., Peiró, S.: Gasto farmacéutico en atención primaria: variables asociadas y asignación de presupuestos de farmacia por zonas de salud. Gac. Sanit. 15, 32–40 (2001)

Healey, A.T., Yule, B.F., Reid, J.P.: Variation in general practice prescribing costs and implications for budget setting. Health Econ 3(1), 1–47 (1994). doi:10.1002/hec.4730030107 CrossRef

Wrobel, M.V., Doshi, J., Stuart, B.C., Briesacher, B.: Predictability of prescription drug expenditures for Medicare beneficiaries. Health Care Financ. Rev 25(2), 37–46 (2003)

García-Goñi, M.: El Ajuste de Riesgos en los mercados sanitarios; Experiencias Europeas. In: Ibern, P. (ed.) Integración asistencial: fundamentos, experiencias y vías de avance, pp. 187–208. Masson, Barcelona (2006)

10.

Thomas, J.W.: Should episode-based economic profiles be risk adjusted to account for differences in patients’ health risks? Health Serv. Res. 41(2):581–598 (2006). doi:10.1111/j.1475-6773.2005.00499.x

11.

Antioch, K.M., Ellis, R.P., Gillett, S., Borovnicar, D., Marshall, R.P.: Risk adjustment policy options for casemix funding: international lessons in financing reform. Eur. J. Health Econ 8, 195–212 (2007). doi:10.1007/s10198-006-0020-7 CrossRef

12.

Van de Ven, W.P.M.M., Ellis, R.P.: Risk adjustment in competitive health plan markets. In: Culyer, A.J., Newhouse, J.P. (eds.) Handbook of health economics. Elsevier, Amsterdam (2000)

13.

Schokkaert, E., Van de Voorde, C.: Belgium: risk adjustment and financial responsibility in a centralised system. Health Policy 65, 5–19 (2003). doi:10.1016/S0168-8510(02)00113-6 CrossRef

14.

Lamers, L.M., Van Vliet, R.C.J.A., Van de Ven, W.P.M.M.: Risk adjusted premium subsidies and risk sharing: key elements of the competitive sickness fund market in the Netherlands. Health Policy 65, 49–62 (2003). doi:10.1016/S0168-8510(02)00116-1 CrossRef

15.

Behrend, C., Buchner, F., Happich, M., Holle, R., Reitmeir, P., Wasem, J.: Risk-adjusted capitation payments: how well do principal inpatient diagnosis-based models work in the German situation? Results from a large data set. Eur. J. Health Econ 8, 31–39 (2007). doi:10.1007/s10198-006-0004-7 CrossRef

16.

Buchner, F., Wasem, J.: Needs for further improvement: risk adjustment in the German Health Insurance System. Health Policy 65, 21–35 (2003). doi:10.1016/S0168-8510(02)00114-8 CrossRef

17.

Beck, K., Spycher, S., Holly, A., Gardiol, L.: Risk adjustment in Switzerland. Health Policy 65, 63–74 (2003). doi:10.1016/S0168-8510(02)00117-3 CrossRef

18.

Shmueli, A., Chernichovsky, D., Zmora, I.: Risk adjustment and risk sharing: the Israeli experience. Health Policy 65, 37–48 (2003). doi:10.1016/S0168-8510(02)00115-X CrossRef

19.

Van de Ven, W.P.M.M., Van Vliet, R.C.J.A., Schut, E., Van Barneveld, E.M.: Access coverage for high-risks in a competitive individual health insurance market: via premium rate restrictions or risk-adjustment premium subsidies? J Health Econ 19, 311–339 (2000). doi:10.1016/S0167-6296(99)00028-4 CrossRef

20.

García-Goñi, M., Ibern, P.: Predictability of drug expenditures: an application using morbidity data. Health Econ 17(1), 119–126 (2008). doi:10.1002/hec.1238 CrossRef

21.

Newhouse, J.P.: Reimbursing health plans and health providers: efficiency in production versus selection. J. Econ. Lit 34, 1236–1263 (1996)

22.

Van Barneveld, E.M., Lamers, L.M., Van Vliet, R.C.J.A., Van de Ven, W.P.M.M.: Risk sharing as a supplement to imperfect capitation in health insurance: a tradeoff between selection and efficiency. J. Health Econ 20, 147–168 (2001). doi:10.1016/S0167-6296(00)00077-1 CrossRef

23.

Van Barneveld, E.M.: Risk sharing as a supplement to imperfect capitation in health insurance: a tradeoff between selection and efficiency. Doctoral dissertation, Erasmus University, Rotterdam (2000)

24.

Van Barneveld, E.M., Lamers, L.M., Van Vliet, R.C.J.A., Van de Ven, W.P.M.M.: Mandatory pooling as a supplement to risk-adjustment capitation payments in a competitive health insurance market. Soc. Sci. Med 47, 223–232 (1997). doi:10.1016/S0277-9536(98)00056-2 CrossRef

25.

Van de Ven, W.P.M.M., Beck, K., et al.: Risk adjustment and risk selection on the sickness fund insurance market in five European countries. Health Policy 65, 75–98 (2003). doi:10.1016/S0168-8510(02)00118-5 CrossRef

26.

Beebe, J.C.: An outlier pool for medicare HMO payments. Health Care Financ. Rev 14(1), 59–63 (1992)

27.

Ellis, R.P., McGuire, T.G.: Insurance principles and the design of prospective payment systems. J. Health Econ 7, 215–237 (1988). doi:10.1016/0167-6296(88)90026-4 CrossRef

28.

Keeler, E.B., Carter, T.: Insurance aspects of DRG outlier payments. J. Health Econ 7, 193–214 (1988). doi:10.1016/0167-6296(88)90025-2 CrossRef

29.

Zhao, Y., Ellis, R.P., Ash, A.S., Calabrese, D., Ayanian, J.Z., Slaughter, J.P., et al.: Measuring population health risks using inpatient diagnoses and outpatient pharmacy data. Health Serv. Res. 36, 180–193 (2001)

30.

Zhao, Y., Ash, A.S., Ellis, R.P., Ayanian, J.Z., Pope, G.C., Bowen, B., et al.: Predicting pharmacy costs and other medical costs using diagnoses and drug claims. Med. Care 43(1), 34–43 (2005)

31.

Dudley, R.A., Medlin, C.A., Hammann, L.B., Cisternas, M.G., Brand, R., Rennie, D.J., et al.: The best of both worlds? The potential of hybrid prospective/concurrent risk adjustment. Med. Care 41(1), 56–69 (2003). doi:10.1097/00005650-200301000-00009 CrossRef

32.

Luft, H.S., Dudley, R.A.: Assessing risk adjustment approaches under non-random selection. Inquiry 41, 203–217 (2004)

33.

Winkelman, R., Mehmud, S.A.: A comparative analysis of claims-based tools for health risk assessment. Society of Actuaries sponsored Research Project. http://www.soa.org/soaweb/files/pdf/risk-assessmentc.pdf (2007). Accessed 21 July 2007

34.

OECD: Health data (2007)

35.

Hughes, J.S., Averill, R.F., Eisenhandler, J., Goldfield, N.I., Muldoon, J., Neff, J.M., et al.: Clinical Risk Groups (CRGs): a classification system for risk-adjusted capitation-based payment and health care management. Med. Care 42(1), 81–90 (2004). doi:10.1097/01.mlr.0000102367.93252.70 CrossRef

36.

Inoriza, J.M., Coderch, J., Carreras, M., Vall-Llosera, L., García-Goñi, M., Lisbona, J.M., Ibern, P.: La medida de la morbilidad atendida en una organización sanitaria integrada. Gac. Sanit. (2008). doi:10.1016/j.gaceta.2008.02.003 CrossRef

37.

Ettner, S.L., Frank, R.G., McGuire, T.G., Hermann, R.C.: Risk adjustment alternatives in paying for behavioral health care under Medicaid. Health Serv. Res 36, 793–811 (2001)

Title: Hybrid risk adjustment for pharmaceutical benefits
Authors: Manuel García-Goñi
Pere Ibern
José María Inoriza
Publication date: 01-07-2009
Publisher: Springer-Verlag
Published in: The European Journal of Health Economics / Issue 3/2009
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-008-0133-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hybrid risk adjustment for pharmaceutical benefits

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Total costs of injury from accidents in the home and during education, sports and leisure activities: estimates for Norway with assessment of uncertainty

Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study

The economic costs of Group B Streptococcus (GBS) disease: prospective cohort study of infants with GBS disease in England

Exploring spatial patterns in general practice expenditure

Material versus social deprivation and health: a case study of an urban area

Cost of skin cancer in England